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ABSTRACT No current patient-centred instrument captures all dimensions of physical activity in
chronic obstructive pulmonary disease (COPD). Our objective was item reduction and initial validation of
two instruments to measure physical activity in COPD.
Physical activity was assessed in a 6-week, randomised, two-way cross-over, multicentre study using
PROactive draft questionnaires (daily and clinical visit versions) and two activity monitors. Item reduction
followed an iterative process including classical and Rasch model analyses, and input from patients and
clinical experts.
236 COPD patients from five European centres were included. Results indicated the concept of physical
activity in COPD had two domains, labelled “amount” and “difficulty”. After item reduction, the daily
PROactive instrument comprised nine items and the clinical visit contained 14. Both demonstrated good
model fit (person separation index >0.7). Confirmatory factor analysis supported the bidimensional structure.
Both instruments had good internal consistency (Cronbach’s α>0.8), test–retest reliability (intraclass
correlation coefficient ⩾0.9) and exhibited moderate-to-high correlations (r>0.6) with related constructs and
very low correlations (r<0.3) with unrelated constructs, providing evidence for construct validity.
Daily and clinical visit “PROactive physical activity in COPD” instruments are hybrid tools combining a
short patient-reported outcome questionnaire and two activity monitor variables which provide simple,
valid and reliable measures of physical activity in COPD patients.
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Introduction
Physical activity is a key factor in determining health status, and its preventative role in chronic diseases is
well accepted [1]. During the past decade, a substantial amount of research on physical activity in patients
with chronic obstructive pulmonary disease (COPD) has been published, prompted initially by studies
showing that low levels of physical activity are associated with poor prognosis [2, 3]. Research has
consistently shown that patients with COPD have lower physical activity levels than their healthy peers [4–7]
and many patients limit their physical activity to avoid symptoms [8]. A recent systematic review of the
determinants and outcomes of physical activity in patients with COPD showed a consistent effect of regular
physical activity in reducing COPD exacerbations and mortality [9]. Hence, physical activity constitutes an
important outcome to clinicians and to patients with COPD.
Current trends in the assessment of physical activity focus on the measures of amount and frequency of
activities using activity monitors [10]. However, it is unlikely that an activity monitor can fully capture
patients’ experience of physical activity. Indeed, qualitative research has shown that patients experience
symptoms while being active, or have to adapt their lifestyle [11], features that will never be captured using
activity monitors alone. Such a patient-centred concept can only be measured through a patient-reported
outcome (PRO) questionnaire, which needs to be developed using data directly from patients with COPD [12].
Conversely, a PRO questionnaire alone will also not allow assessment of physical activity patterns or detection
of small changes in physical activity on a day-to-day basis. Of note, the currently available PROs that aim to
measure physical activity in COPD patients are not based on a conceptual framework [13] and their
development does not follow best practice as set out in the guidelines published by the US Food and Drug
Administration (FDA) [14]. In developing the PROactive tools we hypothesised that items generated from
patient experiences in combination with an activity monitor would capture all relevant dimensions of physical
activity in patients with COPD [11].
Within the framework of the European Union Innovative Medicines Initiative PROactive project (www.
proactivecopd.com) our group first conducted qualitative research and drafted a conceptual framework to
set out the concept of physical activity from patients’ experience and to provide the necessary basis to
generate an item pool for two PROs, one with a daily recall period and one with a 7-day recall period
(daily and clinical visit versions, respectively) to measure the experience of physical activity in patients
with COPD [11]. Our group has also evaluated the validity of six commercial physical activity monitors in
patients with COPD [15, 16]. The aim of the current study was 1) to identify a comprehensive set of
nonredundant items and monitor outputs that can be used to measure physical activity in COPD patients
and 2) to perform an initial validation of the two instruments.
Methods
Study design and sample
A 6-week, randomised, two-way cross-over, multicentre study was conducted in five European medical
centres (fig. 1, further details in the online supplementary material). We recruited both stable and
exacerbated patients with COPD defined by spirometry, to cover the whole range of physical activity. The
study was advised and approved by the PROactive ethics and patient advisory boards, approved by the
ethics committee at each centre and registered at www.clinicaltrials.gov (NCT01388218). Written consent
was obtained from all patients.
Assessments and measures
Figure 1 shows the assessments and timing. In the first 2-week study period patients were randomised to
complete either the daily PROactive item pool, consisting of 30 questions asking patients to report their
physical activity experience on a daily basis, or the clinical visit PROactive item pool, of 35 questions using
a 7-day recall (see online supplementary material). Following a 2-week wash-out patients completed the
other questionnaire during the second study period. Both item pools were developed previously using
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appropriate qualitative research methods and linguistic adaptation for each site [11] in line with current
European Medicines Agency [17] and US FDA published standards [14].
During the study periods (fig. 1), patients wore two accelerometers previously identified during a
systematic review [10] and further validated for COPD patients against the doubly labelled water method
[15] and indirect calirometry [16] (Actigraph G3Tx; Actigraph, Pensacola, FL, USA and Dynaport
MoveMonitor; McRoberts BV, The Hague, The Netherlands).
Statistical analysis
The analysis sets and sample size calculations, as well as the statistical analysis plan were defined a priori
according to objectives (see online supplementary material).
The item reduction process was conducted separately for each PROactive instrument and followed a
systematic iterative process (fig. 2 and online supplementary material). Items were flagged and considered
for removal if they exceeded prespecified thresholds of acceptability [18–25]. We hypothesised a priori that
PROs alone might not capture information on the amount of physical activity well, so both item pools
were analysed alone and in combination with activity data from each monitor (analysed separately).
Confirmatory factor analysis was used to test the fit of the final PROactive Physical Activity in COPD
(PPAC) instruments with the dimensionality identified during the item reduction process [20, 26]. Initial
validation of the item-reduced PPAC instruments comprised reliability (internal consistency and test–retest
reliability) and construct validity (convergent, known-groups and discriminant validity) [23, 27]. All
analyses were performed separately for each instrument and dimension, in case the instruments exhibited
more than one dimension.
Informed consent
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Daily PROactive PRO
Clinical visit PROactive PRO
CRQ, CCQ, CAT
HADS
Physical activity monitors
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COPD history
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Baseline exacerbation
Concomitant therapies
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Body composition
Lung function
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Clinical visit PRO
Activity monitor
Arm 1
Arm 2
Arm 2
Arm 1
Wash-out period
Visit 1
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
Visit 2 Visit 3 Visit 4
Visit 1 Visit 2 Visit 3 Visit 4
Daily PRO
Activity monitor
Clinical visit PRO
Activity monitor
Daily PRO
Activity monitor
FIGURE 1 Study visits and assessments. PRO: patient-reported outcome; CRQ: chronic respiratory questionnaire;
CCQ: clinical chronic obstructive pulmonary disease questionnaire; CAT: chronic obstructive pulmonary disease
assessment test; HADS: hospital anxiety and depression scale; COPD: chronic obstructive pulmonary disease;
mMRC: modified Medical Research Council dyspnoea scale; SAE: serious adverse event; 6MWT: 6-min walk test.
#: assessments could be split between visit 1 and visit 2; ¶: in the exacerbated patients group only.
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Results
236 patients with COPD were included in the study (fig. 1). Patients were mostly male (68%), with mean
±SD age of 67±8 years, forced expiratory volume in 1 s of 57±21% and body mass index of 27±5 kg·m−2.
Baseline characteristics are shown in table 1, and in online supplementary table E1 stratified by site. A
total of 228 patients (97%) had valid (⩾3 days with ⩾10 h wearing time) data from activity monitors,
showing good compliance and moderate levels of physical activity (online supplementary table E2).
Item reduction
The factor analysis, item-to-total and inter-item correlations, and infit and outfit statistics from the Rasch
models suggested that both the daily and clinical visit versions of PPAC (D-PPAC and C-PPAC,
respectively) had a bidimensional structure, with a clear distribution of items in two factors (online
supplementary tables E3 and E4). Consequently, the process of item reduction was performed separately
according to factors 1 “amount of physical activity” and 2 “difficulty with physical activity”.
Tables 2 and 3 detail the reasons for item flagging for exclusion: due to floor or ceiling effects, not fitting
unidimensionality, redundancy, not proper ordering, differential item functioning or less relevant for
patients and/or experts. For the D-PPAC, a total of five iterations in factor 1 (“amount”) allowed a
reduction from nine to four items, including two variables from activity monitors (steps and vector
magnitude unit (VMU)); and in factor 2 (“difficulty”), a total of 12 iterations allowed a reduction from 26
to five items. Full information on item removal is detailed in online supplementary table E5. The final
version of the D-PPAC (see online supplement), described in figure 3, exhibited good performance and
distribution of items, according to the person separation index (PSI) (0.83 in factor 1 with Dynaport, and
0.80 in factor 1 with Actigraph; 0.88 in factor 2) and the person-item map (fig. 4). Confirmatory factor
Unidimensionality:
  Item-to-total score
    correlation
  Inter-item correlation
  Exploratory factor
    analysis
  Infit
  Outfit
Redundancy:
  Infit
  Outfit
Ordering categories: 
  Order
  Person item map
Floor and  
  ceiling effects
X items
Analysis
Y items
Final items
Confirmatory factor analysis
Decision on removing items
Clinical relevance:
  Clinical expert knowledge
  Patient interviews, focus groups, cognitive debriefings
  Analysis results
Advisory board
advice
Differential item  
  functioning
Iterations=n
FIGURE 2 Flowchart of the iterative process for the item reduction process.
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analysis supported the two-factor structure and exhibited appropriate goodness of fit (online
supplementary table E6).
For the C-PPAC, a total of four iterations allowed reduction from nine to four items, including two
variables from activity monitors for factor 1. For factor 2, a total of 16 iterations allowed reduction from
31 to 10 items. The final version of the C-PPAC (see the online supplement), described in figure 3, also
showed good performance and items distribution, as per the PSI (0.75 in factor 1 with Dynaport, 0.74 in
factor 1 with Actigraph, and 0.93 in factor 2) and person-item map (fig. 4). Confirmatory factor analysis
again supported the two factor structure and exhibited appropriate goodness of fit (table E6).
TABLE 1 Baseline demographic and clinical characteristics
Subjects n 236
Disease status at recruitment
Stable 221 (94)
Exacerbated 15 (6)
Age years 67.4±8.4
Male 160 (68)
Primary ethnicity: white 231 (98)
Living alone 117 (50)
Low socioeconomic status (NS-SEC IV–V) 39 (16)
Working status: employed 28 (12)
Current smoker 43 (18)
Smoking pack-years 57.2±40.4
BMI kg·m−2 27.0±5.5
FFMI kg·m−2# 18.1±3.0
FEV1 % pred 57.0±20.5
FVC % pred 95.6±19.6
FEV1/FVC % 46.9±13.2
IC/TLC %# 34.3±9.9
RV/TLC %# 50.9±11.4
TLCO % pred# 59.8±22.7
ATS/ERS stages#
I: mild (FEV1 ⩾80%) 34 (15)
II: moderate (FEV1 <80% and ⩾50%) 108 (46)
III: severe (FEV1 <50% and ⩾30%) 71 (30)
IV: very severe (FEV1 <30%) 22 (9)
6MWD m# 427.7±129.3
Quadriceps strength kg# 31.8±11.8
Any admissions for COPD exacerbation ever 95 (40)
Comorbidities
Coronary heart disease 28 (12)
Any cardiovascular disease or disorder¶ 127 (54)
Diabetes 21 (9)
Musculoskeletal disorders 27 (11)
Dyspnoea (mMRC 0–4) 1.7 (1.1)
CRQ dyspnoea# 4.8 (1.5)
CRQ fatigue# 4.3 (1.3)
CRQ emotional# 4.9 (1.3)
CRQ mastery# 5.3 (1.3)
CCQ total# 1.9 (1.1)
CAT# 15.1 (8.2)
HADS anxiety# 5.6 (4.2)
HADS depression# 5.0 (3.4)
Data are presented as n, n (%) or mean±SD. NS-SEC: National Statistics Socio-economic Classification;
BMI: body mass index; FFMI: fat-free mass index; FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity; IC: inspiratory capacity; TLC: total lung capacity; RV: residual volume: TLCO: transfer factor of the
lung for carbon monoxide; ATS: American Thoracic Society; ERS: European Respiratory Society; 6MWD:
6-min walking distance; COPD: chronic obstructive pulmonary disease; mMRC: modified Medical Research
Council dyspnoea scale; CRQ: chronic respiratory questionnaire; CCQ: clinical COPD questionnaire; CAT:
COPD assessment test; HADS: hospital anxiety and depression scale. #: some values are missing for
certain variables (FFMI n=9, IC/TLC n=15, RV/TLC n=14, TLCO n=8, 6MWD n=3, quadriceps strength n=3,
CRQ dyspnoea n=88, CRQ fatigue n=3, CRQ emotional n=3, CRQ mastery n=3, CCQ n=1, CAT n=2, HADS
anxiety n=1, HADS depression n=1); ¶: including coronary heart disease.
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TABLE 2 Performance of all items of the daily version of PROactive Physical Activity in COPD (chronic obstructive pulmonary disease) instrument (D-PPAC) and
activity monitors during item reduction
Item flagged due to Selected
item
Floor/ceiling
effect
Not fitting
unidimensionality
Redundancy Not proper
order
Differential Item
Functioning
Less important
according to
patients/experts
Factor 1 “Amount of physical activity”
Walking outside x
Chores inside x x x
Chores outside x
Physical leisure x x
Intensity# x
Time in locomotion# x
Standing time# x x x
VMU·min−1# x
Steps# x
MVPA¶ x x
VMU·min−1¶ x
Steps¶ x
Factor 2 “Difficulty with physical activity”
Difficulty getting dressed x
Difficulty carrying things x x x
Difficulty climbing stairs x x x x
Difficulty showering x x x
Difficulty taking a bath x x x
Difficulty bending over x x x
Difficulty washing yourself x x x
Difficulty walking up a small slope x x x
Difficulty when hurrying x x
Avoid activities x
Breathless in general x
Lack physical strength x x
Lack of strength in legs x x
Tired in general x
Take breaks x
Pace yourself x x
Prevented from doing activities x x
Breathless walking on level ground x x
Slow down while walking x x
Breathless climbing stairs x x
Time to recover x x
Spread activities x x
Stop doing activities x x x
Puffs in addition x x x
Consider lung problems when planning x x
Help from others x x x x x
VMU: vector magnitude unit; MVPA: moderate-to-vigorous physical activity. #: data from Dynaport; ¶: data from Actigraph.
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TABLE 3 Performance of all items of the clinical visit version of PROactive Physical Activity in COPD (chronic obstructive pulmonary disease) instrument (C-PPAC)
and activity monitors during item reduction
Item flagged due to Selected item
Floor/ceiling effect Not fitting unidimensionality Redundancy Not proper order Differential item functioning Less important according
to patients/experts
Factor 1 “Amount of physical activity”
Walking outside# x x
Chores inside x x x
Chores outside x
Physical leisure x x
Exercise to maintain or improve physical x x
Intensity¶ x
Time in locomotion¶ x
Standing time¶ x x x
VMU·min−1¶ x
Steps¶ x
MVPA§ x x
VMU·min−1§ x
Steps§ x
Factor 2 “Difficulty with physical activity”
Difficulty getting dressed x
Difficulty carrying objects x x x
Difficulty climbing stairs x x x
Difficulty showering x x x x
Difficulty bathing x x x
Difficulty bending over x x x x
Difficulty washing yourself x x x
Difficulty walking up small slope x
Difficulty getting out and about x
Difficulty when hurrying x x
Avoid activities x
Breathless in general x
Lack physical strength x
Lack of strength in legs x x
Tired in general x
Take breaks x
Pace yourself x x
Prevent doing activities x x
Cough during activities x x
Breathless walking on level ground x
Slow down while walking x x
Breathless climbing stairs x x
Time to recover x
Spread activities x
Stop doing activities x x
Puffs in addition x x
Consider lung problems when planning x
Help from others x x x
Use aids to facilitate activities x x x x
Overexert yourself during activities x x
VMU: vector magnitude unit; MVPA: moderate-to-vigorous physical activity; #: item flagged because the original response categories did not show proper ordering; after collapsing the
last two categories the item showed no ordering problems and therefore it was not removed. ¶: data from Dynaport; §: data from Actigraph.
994
D
O
I:10.1183/09031936.00183014
C
O
P
D
|
E.G
IM
EN
O
-SA
N
TO
S
ET
A
L.
Several analyses were performed to select cut-off points for activity monitor variables to achieve optimal
performance of the PPAC instruments. Because cut-offs were not identical between Actigraph and
Dynaport, we determined agreement between the variables from the two monitors (complete methods are
described in the online supplement) and observed 91% agreement for steps and 88% for VMU in the daily
instrument, and 82% and 96% for steps and VMU, respectively, in the clinical visit version.
Complementary analyses using PRO data alone for factor 1 (i.e. excluding activity monitor data) showed
that neither the D-PPAC nor the C-PPAC achieved optimal performance or discrimination. Specifically, all
items exhibited low item-to-total correlation, some of them were flagged due to floor effect, redundancy,
ordering problems and differential item functioning, and the PSI values decreased from 0.83 to 0.59 and
from 0.75 to 0.62 in the daily and clinical visit versions, respectively, when the item reduction process did
not include variables from the activity monitors (online supplementary table E7 and fig. E1). Taken
together, the data show that the combination of PRO and monitor data resulted in better measurement
properties than either PRO or monitor data alone.
Both PPAC instruments can be scored as a simple sum of the scores of the items (mostly from 0 to 4), with
lower scores indicating poorer physical activity. The final PROactive scores exhibited no differences by sex,
although they demonstrated lower values in the most severe COPD patients (online supplementary table E8).
Reliability and construct validity
Both PPAC instruments showed strong internal consistency and test–retest reliability (table 4 and online
supplementary figs E2 and E3). In both PPAC instruments, factor 1 (“amount of physical activity”)
exhibited weak correlations with health-related quality of life and moderate correlations with dyspnoea and
exercise capacity, while factor 2 (“difficulty with physical activity”) scores showed moderate-to-strong
Physical activitya) Daily version
Amount of physical activity
How much walking did you do outside today?
How many chores did you do outside the house today?
+
Daily steps
Daily vector magnitude units
How much difficulty did you have getting dressed today?
How often did you avoid doing activities because of your lung problems today?
How breathless were you in general during your activities today?
How tired were you in general during your activities today?
How often did you have to take breaks during your physical activities today?
Difficulty during physical activity
Physical activityb) Clinical visit version
Amount of physical activity
In the past 7 days, how much walking did you do outside?
In the past 7 days, how many chores did you do outside 
  the house?
+
Weekly steps
Weekly vector magnitude units
In the past 7 days, how much difficulty did you have getting dressed?
In the past 7 days, how much difficulty did you have getting out and about?
In the past 7 days, how often did you avoid doing activities because of your 
  lung problems?
In the past 7 days, how breathless were you in general during your activities?
In the past 7 days, how often did you lack physical strength to do things because 
  of your lung problems?
In the past 7 days, how tired were you in general during your activities?
In the past 7 days, how often did you have to take breaks during your 
  physical activities?
In the past 7 days, how breathless were you when walking on level ground
  indoors and outdoors?
In the past 7 days, how much time did you need to recover from your 
  physical activities?
In the past 7 days, did you need to consider your lung problems when you
  planned your activities because of your lung problems?
Difficulty during physical activity
FIGURE 3 Conceptual frameworks of a) the daily version of PROactive Physical Activity in COPD (chronic obstructive pulmonary disease) (D-PPAC)
and b) the clinical visit version of PROactive Physical Activity in COPD (C-PPAC) instruments: final domains and items.
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FIGURE 4 Person-item maps and overall fit of the model for factors 1 (“amount”) and 2 (“difficulty”) of the daily version of PROactive physical
activity in COPD (chronic obstructive pulmonary disease) (D-PPAC) and the clinical visit version of the PROactive Physical Activity in COPD
(C-PPAC) instruments. These plots indicate that the final items are well targeted to the patients and cover a wide range of the factor measured.
Person separation index (PSI) values indicate that each factor is precise enough to differentiate between different patients’ physical activity
experiences. a) D-PPAC final items of factor 1 in combination with final variables of Dynaport; b) C-PPAC final items of factor 1 in combination
with final variables of Dynaport; c) D-PPAC final items of factor 1 in combination with final variables of Actigraph; d) C-PPAC final items of factor
1 in combination with final variables of Actigraph; e) D-PPAC final items of factor 2; f ) C-PPAC final items of factor 2.
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correlations with health-related quality of life, dyspnoea and exercise capacity (table 5). Known-groups
validity was good in both instruments, with PPAC scores differentiating across grades of dyspnoea, stable
from exacerbated patients at baseline and tertiles of physical activity levels (using variables not included in
the PPAC scoring, such as intensity) (online supplementary table E9). All correlations with unrelated
constructs such as height, socioeconomic status and baseline heart rate were weak; supporting the
discriminant validity of both PPAC instruments (online supplementary table E10).
Discussion
Our analyses resulted in two innovative reliable and valid instruments to fully evaluate the concept of
physical activity in patients with COPD: the daily (D-PPAC) and the clinical visit (C-PPAC) versions of
the PROactive instruments. The PPAC instruments are hybrid tools that combine PRO and activity
monitors to assess physical activity. Interestingly, the C-PPAC turned out to have nearly twice as many
items as the D-PPAC. We are not surprised by this fact, because some activities are not performed every
day although they are covered in a 1-week period, therefore data about difficulties with such activities may
not be captured with a 1-day-recall item but are captured with a 1-week-recall item.
The first important finding of the study confirms that the concept “physical activity” in patients with COPD
has two domains, which we labelled “amount of physical activity” and “difficulty with physical activity”. The
TABLE 4 Internal consistency and test–retest reliability of the daily and clinical visit versions of PROactive Physical Activity in
COPD (chronic obstructive pulmonary disease) instruments (D-PPAC and C-PPAC, respectively)
Cronbach’s α ICC§
Examination 1# Examination 2¶ Weekly+ Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
D-PPAC
Factor 1: amount with Dynaport 0.862 0.845 0.92 0.74 0.84 0.80 0.74 0.75 0.88 0.86
Factor 1: amount with Actigraph 0.860 0.839 0.93 0.81 0.81 0.82 0.73 0.71 0.87 0.87
Factor 2: difficulty 0.944 0.951 0.93 0.71 0.84 0.85 0.89 0.79 0.84 0.85
C-PPAC
Factor 1: amount with Dynaport 0.813 0.800 0.92
Factor 1: amount with Actigraph 0.803 0.781 0.90
Factor 2: difficulty 0.927 0.940 0.90
ICC: intraclass correlation coefficient. #: For D-PPAC the mean value for the first 7 days of daily assessments (week 1 for arm 1/week 5 for
arm 2) and for C-PPAC the value for the first assessment (visit 3 for arm 1/visit 1 for arm 2); ¶: for D-PPAC the mean for the second 7 days of
daily assessments (week 2 for arm 1/week 6 for arm 2) and for C-PPAC the value for the second assessment (visit 4 for arm 1/visit 2 for arm
2); +: comparison of mean values from week 1 with mean values from week 2 for D-PPAC, and comparison of first and second administration
for each patient (week 1 and week 2 in arm 1, and week 3 and week 4 in arm 2) for C-PPAC; §: for patients randomised to arm 1, the score
from day 1 in week 1 was compared to the score from day 1 in week 2, the score from day 2 in week 1 was compared to the score from day 2
in week 2, and so on. For patients randomised to arm 2, the score from day 1 in week 5 was compared to the score from day 1 in week 6, the
score from day 2 in week 5 was compared to the score from day 2 in week 6, and so on.
TABLE 5 Correlation of daily and clinical visit versions of PROactive Physical Activity in COPD
(chronic obstructive pulmonary disease) instruments (D-PPAC and C-PPAC, respectively) with
health status, dyspnoea and exercise capacity (convergent validity)
CRQ dyspnoea CRQ fatigue CCQ total CAT mMRC 6MWD
D-PPAC
Factor 1: amount with Dynaport 0.36* 0.18* −0.20* −0.23* −0.42* 0.55*
Factor 1: amount with Actigraph 0.34* 0.17* −0.19* −0.20* −0.41* 0.55*
Factor 2: difficulty 0.74* 0.66* −0.72* −0.66* −0.56* 0.41*
C-PPAC
Factor 1: amount with Dynaport 0.36* 0.37* −0.37* −0.38* −0.53* 0.62*
Factor 1: amount with Actigraph 0.35* 0.36* −0.34* −0.37* −0.55* 0.65*
Factor 2: difficulty 0.86* 0.73* −0.85* −0.82* −0.70* 0.49*
Bold type represents the observed correlations agreed with the expected correlations set by a panel of
experts. CRQ: chronic respiratory questionnaire; CCQ: clinical COPD questionnaire; CAT: COPD assessment
test; mMRC: modified Medical Research Council dyspnoea scale; 6MWD: 6-min walking distance. *: p<0.05.
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“amount” domain is covered by two PRO items (amount of walking outside and chores outside) and by two
variables from the activity monitor (steps and VMU), in both PPAC instruments. The inclusion of other items
or activity monitor outputs did not enrich the final score. The combination of PRO and activity monitor data
yields a much more robust measure of “amount” than either of the components, a unique observation from
our study. The “difficulty” domain contains only PRO items and includes items about avoiding or pacing
activities and breathlessness during activities. Demonstrating that physical activity is structured in two domains
concurs with our qualitative research of experience of physical activity where COPD patients universally
described three themes: “amount of”, “symptoms during” and “adaptations to” [11]. Based on the analysis of
this study, the themes “symptoms” and “adaptations” merged into a single domain (“difficulty”).
The second relevant finding is that the final PPAC instruments are hybrid tools combining PRO and
activity monitors for the assessment of amount of physical activity in COPD patients. Our comprehensive
analyses clearly showed that neither PRO nor activity monitors alone could discriminate well (PSI<0.4)
within the latent patient-centred construct “amount of physical activity”, while the combination of both
tools achieved good discrimination at all ranges of the scale. Restricting assessment to either a PRO or an
activity monitor does not provide a complete measure of the amount of physical activity. It is possible that
activity monitors do not totally capture activities of low intensity, or that relevant activity is not
appropriately recalled by patients.
It could be argued that the combination of the PRO with the accelerometer may impair the use of the
PPAC instruments. However, the use of activity monitors is becoming more frequent both in clinical
practice [10] and in clinical trials [28–30]. In addition, research shows limitations in using only
questionnaires for assessing physical activity [13]. The patient-centred development of the PPAC
instruments provides comprehensive assessment of physical activity incorporating the patient viewpoint.
Importantly, the PPAC instruments will not be limited to the two activity monitors reported in this paper:
other activity monitors can be combined with the PRO items after appropriate validation is complete.
It could be argued that some of the excluded items should have been kept in the PPAC instruments due to
their clinical relevance. For example, in the “amount” domain, no items about activities inside the house
were kept. The item “chores inside the house” did not fit well with the rest of the items according to
exploratory factor analysis and showed differential item functioning between males and females (online
supplementary table E5). In addition, some male patients did not understand the item during interviews
or cognitive debriefings because they considered this item to be more relevant to females. Two items about
outside activities were included (“walking outside” and “chores outside”). Although superficially similar,
these two items increased discrimination and covered different parts of the range of physical activity, as
shown in PSI values and person-item maps. Interestingly, they completely overlapped with the range
covered by “chores inside”. Finally, VMU, a variable from the activity monitors, showed the best
discriminant ability at low amounts of activity (online supplementary fig. E1), suggesting that it
conceptually covers what the item “chores inside” was not able to capture.
The item “difficulty climbing stairs” could seem to be important because climbing stairs represents a
substantial effort, and was also identified by patients as a priority during interviews and focus groups [11].
However, Rasch analysis showed improper ordering of the item, suggested a poor fit with the other items,
presented a floor effect and showed high correlation with other remaining items in the difficulty domain
(online supplementary table E5). Both “chores inside the house” and “difficulty climbing stairs” are
examples of items that are intuitively relevant which were removed based on corroborating arguments
from different sources (statistics and qualitative studies).
Both PPAC instruments demonstrated construct validity, showing ability to measure the construct that they
intended to measure. As expected, “amount” scores exhibited weak correlations with health status, and
moderate correlations with dyspnoea and exercise capacity, while “difficulty” scores showed
moderate-to-strong correlations with health status, dyspnoea and exercise capacity. Additionally, all
correlations were <0.9, demonstrating that the PPAC instruments provide different information than
existing scales, i.e. that PPAC instruments indeed measure physical activity and not exercise capacity or
health status [23]. Similarly, the instruments showed good known-groups validity when comparing across
previously defined groups, detecting differences in physical activity (using variables not included in the
PPAC scoring) between them. Finally, the discriminant validity showed that the difficulty and amount
domains from the PPAC instruments were unrelated (predefined as correlation <0.3) to the constructs that
were expected to be unrelated such as patient height. In comparison with previous studies that aimed to
validate questionnaires to measure physical activity in patients with COPD, our instruments exhibited
better correlations for convergent validity. For example, correlations of ∼0.37 were found between the
several outputs from the Yale Physical Activity Survey and the 6-min walking distance [31], compared to
correlations of ∼0.55 in our instruments.
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Measuring the experience of physical activity is important for COPD management because physical
activity is important from the patient’s perspective [11] and thus for their daily life, and no valid
instruments are currently available to capture it. In particular, because patients report that treatments
(which need not be limited to pharmacological approaches) that improve physical activity are of value to
them [11], the availability of PPAC tools which have been developed in line with current guidance will
help future clinical trials aiming to include physical activity as an regulatory-accepted outcome [14].
A strength of this study is that the instruments were developed according to current best practice [14, 17],
and their psychometric properties were rigorously tested using appropriate methodology and predefined
and rigorous statistical procedures [32]. Both the D-PPAC and the C-PPAC item pools were developed
through a systematic process of literature reviews [12, 13], input from experts and, as recommended [33–35],
input from patients through qualitative research using one-to-one interviews, focus groups and cognitive
debriefing interviews. Patients recruited were representative of a wide spectrum of COPD disease severity,
comorbidities and different geographical and cultural backgrounds [11]. The information from this
qualitative research was also used during the item reduction process when deciding to remove or keep an
item. An advisory board provided advice to guide the whole process for the item reduction and validation of
the tools. Moreover, the item reduction and initial validation reported here were also based on a
heterogeneous sample of patients with COPD that covered a whole range of physical activity and other
clinical determinants.
Another strength of the PPAC instruments is that they are based on a conceptual framework. A systematic
review identified the absence of a conceptual framework of physical activity in all existing instruments to
assess it in patients with COPD [13], which raises doubts about the validity of these instruments. We
drafted an initial conceptual framework from extensive patient input and literature review [11], which was
refined after item reduction and confirmed using appropriate statistical methods.
Our study has some limitations. Firstly, although the sample size was sufficient and the population was
quite heterogeneous to achieve the objective of the study, further validation is needed in specific subgroups
of patients with COPD. For example, the person item maps of the “difficulty” domain (factor 2) suggest
that our instruments perhaps cover patients with greater difficulty in physical activity than the difficulty
shown by patients in our sample, since the person distribution is skewed to the lower end of the scale.
Secondly, the PPAC instruments have been validated only in a European population and using only three
different languages. Further studies are ongoing to validate the PPAC instruments in patients with both
milder and more severe COPD, from other countries and using validated translations of the instruments.
In the same way, additional studies are required to confirm the best scoring system for the PPAC
instruments, to assess responsiveness to change due to interventions and to define levels of response.
In conclusion, both the D-PPAC and the C-PPAC, combining a short list of PRO items and two activity
monitor variables, provide a simple, valid and reliable measure of physical activity in COPD patients.
These tools will be further evaluated in different clinical situations and for responsiveness to drug and
nondrug interventions.
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